INTRODUCTION
============

*Aeromonas hydrophila* is among the most common species associated with wound and soft tissue infections, gastroenteritis and septicaemia in the host ([@r8]; [@r25]). Our laboratory group and others have characterized several virulence factors from *Aeromonas* species, which are secreted via the type 2 and type 3 secretion systems ([@r6]; [@r9]; [@r43], [@r44]; [@r45]; [@r52]; [@r57]). Our most recent studies are focused on the type 6 secretion system (T6SS) and its effectors from diarrhoeal isolate SSU of *A. hydrophila* ([@r49], [@r50]). Although the T6SS is highly conserved in *Proteobacteria*, the general mechanism as to how this system operates remains poorly understood ([@r11]).

*A. hydrophila* SSU has one chromosomally located T6SS gene cluster which is regulated by the *σ*^54^ activator encoded by the virulence-associated gene, *vasH* ([@r49]). We reported that the Δ*vasH* mutant of *A. hydrophila* SSU was unable to express genes encoding haemolysin-coregulated protein (Hcp) and the valine glycine repeat G (VgrG) family of proteins VgrG2 and VgrG3, which constitute part of the T6SS gene cluster ([@r49]). However, this mutant was able to express, but was unable to secrete or translocate, VgrG1 that resides outside of the T6SS gene cluster ([@r50]). Further, deletion of *hcp* or *vgrG* prevents secretion of the other, thereby demonstrating dual roles of Hcp and VgrG as structural components of the T6SS apparatus and as effector proteins ([@r7]). Importantly, both Hcp and VgrG proteins represent a hallmark of the T6SS secreted proteins in all of the bacteria that possess this system ([@r5]; [@r7]; [@r17]; [@r40]). Although the role of VgrG1 in bacterial virulence was convincingly demonstrated recently by us in *A. hydrophila* SSU ([@r50]) and *V. cholerae* ([@r30]; [@r29]), the mechanism of Hcp in modulating the organism\'s virulence is poorly understood.

Innate immunity is the first line of host defence against the challenged organisms, and pattern recognition receptors sense different microbial ligands (known as pathogen-associated molecular patterns, PAMPs) ([@r3]; [@r26]; [@r33]; [@r53]), resulting in the triggering of signalling cascades that determine the host immune response by modulating maturation, activation and recruitment of cellular effectors \[e.g. neutrophils, macrophages, dendritic cells (DCs) and natural killer cells\] ([@r21]; [@r23]; [@r33]; [@r38]).

Phagocytosis is crucial for both innate and adaptive immunity ([@r10]; [@r21]; [@r33]), and macrophages and DCs are professional antigen-presenting cells which act as tissue sentinels and are able to present antigens to naïve T-cells ([@r19]; [@r23], [@r24]). Bacteria have developed different mechanisms to avoid innate immunity ranging from their ability to avoid recognition by toll-like receptor-4 ([@r16]; [@r20]; [@r27]), altering antigenicity of surface molecules to avoid phagocytosis ([@r42]), interfering with mitogen-activated protein kinase signalling cascades ([@r37]; [@r51]; [@r54]), modulating actin polymerization and apoptosis ([@r1]; [@r39]; [@r41]; [@r56]), manipulating phagosome trafficking and maturation ([@r15]; [@r48]; [@r55]), and inducing the production of immunosuppressive cytokines, particularly interleukin (IL)-10. The latter mechanism avoids activation of macrophages, maturation of DCs and recruitment of granulocytes ([@r32]; [@r47]; [@r59]).

Previously, we demonstrated that *A. hydrophila* SSU Δ*vasH* and Δ*vasK* mutants were easily phagocytosed by murine RAW 264.7 macrophages compared with the phagocytosis of wild-type (WT) bacteria ([@r49]). Further, we showed that the Δ*vasH* mutant strain did not express the gene encoding Hcp and that the Δ*vasK* mutant was able to produce Hcp, but was unable to secrete it ([@r49]). Hence, we hypothesized that the secreted form of Hcp could be playing a role in inhibition of phagocytosis of *A. hydrophila* SSU by macrophages. Here, we report that Hcp indeed played a role in modulating the innate immunity by inhibiting the phagocytosis of *A. hydrophila* SSU, thus allowing its multiplication and spread to different organs of the host. Our results show that Hcp is able to bind to macrophages and induce the production of IL-10 and transforming growth factor (TGF)-*β*, affecting the activation and maturation of macrophages, and, consequently, the recruitment of other cellular immune components needed to clear bacterial infection.

METHODS
=======

Cell line and bacterial strains.
--------------------------------

RAW 264.7, a murine macrophage cell line, was maintained in Dulbecco\'s modified eagle medium with high glucose (DMEM) (Invitrogen), supplemented with 10 % fetal bovine serum (FBS) under standard cell culture growth conditions.

*A. hydrophila* SSU Δ*act* (*act* encodes the type 2 secretion system-secreted cytotoxic enterotoxin) ([@r58]) and Δ*act/*Δ*vasH* isogenic mutant strains were developed in the laboratory as described previously ([@r49]). These mutants were grown in LB medium supplemented with kanamycin (50 μg ml^−1^) for *A. hydrophila* Δ*act*, and kanamycin, streptomycin (40 μg ml^−1^) and spectinomycin (50 μg ml^−1^) for the *A. hydrophila* Δ*act/*Δ*vasH* mutant.

Recombinant Hcp protein.
------------------------

The *hcp* (*hcp2* residing within the T6SS cluster) gene was cloned in the pET-30a vector for the production of recombinant protein as reported previously ([@r49]). rHcp containing a 6× His tag was purified by nickel affinity chromatography, dialysed against PBS, and then passed through a polymyxin column (Bio-Rad) to remove any residual lipopolysaccharide (LPS). The pass-through fraction was filtered by using a 0.2 μm filter, and the protein concentration was quantified by using the Bradford assay (Bio-Rad). The removal of LPS from rHcp was verified by the Limulus amebocyte lysate assay (Pyrosate-Dial Medical Supply), and the purity of rHcp was verified by Coomassie Blue staining of the gel.

Cell viability.
---------------

To determine host cell viability (RAW 264.7 cells treated with 10 μg rHcp ml^−1^ for different time periods), we performed the 7-amino actinomycin D (7-AAD) (Becton Dickinson) and the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) (Chemicon) assays, as described previously ([@r45]).

Conditioned medium.
-------------------

To obtain conditioned medium containing Hcp, we grew the Δ*act* mutant strain of *A. hydrophila* SSU (1×10^7^ c.f.u.) in 3 ml DMEM supplemented with 0.5 % FBS at 37 °C. After 2 h, the bacteria were removed by centrifugation, and the supernatant was passed through a 0.2 μm membrane filter. The resulting medium was tested by Western blot analysis for the presence of Hcp by using specific antibodies, and used immediately in the phagocytosis assay.

Western blot analysis.
----------------------

Western blot analysis was performed to detect Hcp in the conditioned medium collected after infection of RAW 264.7 cells with various strains of *A. hydrophila*. Briefly, tissue culture supernatant was filtered by using a 0.2 μm filter to remove bacteria; proteins in the supernatant were separated by using 15 % SDS-PAGE. The proteins were then transferred to a nitrocellulose membrane which was blocked with 5 % skimmed milk+1 % BSA overnight at 4 °C. Mouse--anti-Hcp serum was used at a dilution of 1 : 2000 for 1 h, and horseradish peroxidase-conjugated, goat--anti-mouse antibodies were used at a dilution of 1 : 5000 for 45 min. The blot was then developed by using ECL-Western blotting detection reagent (GE Healthcare).

Phagocytosis assay.
-------------------

Briefly, 1.5×10^6^ RAW 264.7 cells suspended in 1 ml DMEM supplemented with 0.5 % FBS were split into aliquots in polypropylene tubes (12×75 mm). Different bacterial strains were added at an m.o.i. of 10 for 30 min. Then, the cell suspension was centrifuged at 250 ***g*** for 5 min and the supernatant was removed. The pellet was resuspended in 500 μl of DMEM plus 0.5 % FBS (above) and 250 μg gentamicin ml^−1^ (CellGro) to kill extracellular bacteria. After 2 h, the macrophages were washed three times with 1 ml DMEM to remove dead bacteria and gentamicin. The host cells were lysed in 500 μl sterile water, and the cell lysates were plated on LB agar plates containing kanamycin (50 μg ml^−1^) to determine c.f.u. ([@r49]). We examined complete lysis of the host cells under the microscope before plating the cell lysates.

Animal survival.
----------------

Groups of 10 Swiss Webster female mice (Charles River) were challenged via the intraperitoneal (i.p.) route with a sublethal dose of *A. hydrophila* Δ*act/*Δ*vasH* mutant, either alone or in combination with different amounts of rHcp (1--10 μg). As a control, a group of mice was challenged with either the highest dose of rHcp (10 μg) or the Δ*act* parental strain. The survival of mice was followed for 16 days post-infection.

Bacterial spread.
-----------------

Mice were infected via the i.p. route with a sublethal dose of *A. hydrophila* Δ*act/*Δ*vasH* mutant alone or in combination with rHcp (10 μg). The animals were euthanized after 48 h, and sections of liver, spleen and lungs were homogenized and used to determine bacterial burden ([@r2]).

Intraperitoneal lavage.
-----------------------

After 4 h of challenge of mice via the i.p. route with a sublethal dose of *A. hydrophila* Δ*act/*Δ*vasH* mutant alone or in combination with rHcp, the animals were euthanized, and the peritoneal cavity was flushed with 1.5 ml sterile Hanks\' solution (Invitrogen). The lavage was collected and centrifuged at 250 ***g*** for 5 min. The supernatant was used for evaluating various cytokines/chemokines by the multiplex bead array, and the pellets containing host cells were used to determine their phenotypes by flow cytometry (see below).

Hcp-binding assay.
------------------

The whole cell population from the intraperitoneal lavage of mice was incubated with rHcp (10 μg ml^−1^) for 1 h. Then, the cells were incubated for 30 min with anti-mouse CD16/CD32 antibodies (Becton Dickinson). Next, the cells were dispensed into different tubes and incubated with pre-immune mouse serum (1 : 100) as an isotype control, or with the mouse anti-Hcp serum (1 : 100) for 1 h. Subsequently, the host cells were incubated with Alexa Fluor 488-conjugated goat anti-mouse antibodies (Invitrogen) for 45 min, followed by incubations with PE-Cy5-conjugated anti-mouse F4/80, PE-conjugated anti-mouse Gr-1 antibodies, and their respective isotype controls. Between steps, the cells were washed twice with chilled Hanks\' solution, and all the incubations were performed on ice. The cells were acquired in a FACScanto (Becton Dickinson) flow cytometer and analysed by using FACSDiva software (Becton Dickinson).

Quantification of Hcp produced by the Δ*act* mutant of *A. hydrophila* SSU.
---------------------------------------------------------------------------

To determine the amount of Hcp produced by the parental *A. hydrophila* strain in the mouse peritoneum after 4 h of infection, we infected animals via the i.p. route with 3×10^7^ bacterial cells per animal. Subsequently, the animals were euthanized and the intraperitoneal cavity was flushed with 3 ml Hanks\' solution. This lavage was filtered by using 0.2 μm membrane filters and precipitated with 10 % (final concentration) TCA. The protein pellet was resuspended in 500 μl SDS loading buffer, and 20 μl was separated by using 6--15 % SDS-PAGE. In parallel, different concentrations of rHcp were loaded on a similar gel to build a standard curve. Proteins from both the gels were transferred to nitrocellulose membranes, and Western blot analysis was performed using anti-rHcp antibodies. X-ray films obtained after exposure of the membranes were analysed by densitometry, and the concentration of Hcp present in the intraperitoneal lavage was determined from the standard curve.

Cytokines.
----------

The supernatants obtained after intraperitoneal lavages of mice (see Intraperitoneal lavage) were tested for cytokine/chemokine levels by a multiplex bead array (Millipore) following the manufacturer\'s instructions. The data were acquired and analysed in a Bioplex 200 system which uses Bioplex manager software v.5.0 (Bio-Rad).

We measured levels of TGF-*β* in the intraperitoneal lavage supernatant samples by using an ELISA (eBiosciences) and following the manufacturer\'s instructions. The colour reaction was read in a microplate reader Versa-max (Molecular Devices).

Flow cytometry.
---------------

Cell pellets collected after intraperitoneal lavages of mice (see Intraperitoneal lavage) were stained with a panel of antibodies conjugated with FITC (anti-CD11c, anti-CD69), PE (anti-Gr-1, anti-MHC-class II) and PE-Cy5 (anti-F4/80) for flow cytometry (eBiosciences). The cells were incubated with antibodies for 1 h and then washed twice with 1 ml PBS and fixed with 2 % paraformaldehyde. The cells were acquired in a FACScan and analysed by FACSdiva software (Becton Dickinson). Prior to incubation with antibodies, receptors Fc*γ* III/II were blocked using anti-CD16/CD32 antibodies (BD Pharmingen) for 30 min.

Statistical analysis.
---------------------

The data were analysed by one-way ANOVA and Tukey\'s post-test with GraphPad Prism version 4 software, and the animal survival curves were analysed by the Logrank test. At least three independent experiments were performed to represent biological replicates, unless otherwise stated.

RESULTS
=======

Hcp inhibits the phagocytosis of *A. hydrophila* SSU Δ*act/*Δ*vasH* mutant *in vitro*
-------------------------------------------------------------------------------------

Since the secretion of Hcp was affected in both the Δ*vasH* and Δ*vasK* mutant strains ([@r49]), we hypothesized that the secreted form of Hcp could be playing a role in the bacterial inhibition of phagocytosis. To test this, we used conditioned medium from the Δ*act* parental strain of *A. hydrophila* which contained Hcp (Fig. [1a](#f1){ref-type="fig"}) in the phagocytosis assay. Consequently, RAW 264.7 murine macrophages were infected with the Δ*act/*Δ*vasH* mutant in the conditioned medium, thus allowing complementation of the mutant with exogenous Hcp protein. We noted that the ability of the *A. hydrophila* Δ*act/*Δ*vasH* mutant to be phagocytosed by macrophages was reduced in the presence of Hcp (Fig. [1b](#f1){ref-type="fig"}). To confirm that this effect was indeed due to Hcp and not to other secreted bacterial proteins, we performed a phagocytosis assay by using the Δ*act/*Δ*vasH* mutant in conjunction with different concentrations of purified rHcp. We found that phagocytosis of the mutant by macrophages was inhibited by rHcp in a dose-dependent fashion, with statistically significant differences observed at rHcp doses of 5.6 μg and greater (Fig. [1c](#f1){ref-type="fig"}) compared with mutant bacteria (Δ*act*/Δ*vasH*) alone without rHcp.

To determine whether the doses of rHcp necessary to inhibit phagocytosis in our *in vitro* experiments were physiologically relevant, we measured the amounts of Hcp produced by the parental Δ*act* mutant strain of *A. hydrophila* in the mouse peritoneum and we found 8--10 μg Hcp after 4 h of infection, indicating physiological relevance of the rHcp doses used in this study (Fig. [1c](#f1){ref-type="fig"}). Our positive and negative controls in this assay included macrophages infected with the Δ*act* and Δ*act*/Δ*vasH* strains of *A. hydrophila*, respectively. As expected, the former showed minimal phagocytosis, while the latter exhibited much higher levels of phagocytosis by macrophages. These data clearly indicate that the secreted Hcp plays a role in bacterial phagocytosis. We confirmed that the difference in phagocytosis between the parental Δ*act* strain of *A. hydrophila* and that of the Δ*act/*Δ*vasH* mutant was not due to differences in their growth rates (Supplementary Fig. S1a, available with the online version of this paper) or to toxic effects of rHcp on RAW 264.7 cells for at least up to 6 h, as determined by MTT and 7-AAD assays (Supplementary Fig. S1b, c), and as well as by microscopic visualization of host cells (data not shown). The purity of rHcp was evaluated by Coomassie-Blue-staining of the gel (Fig. [1c](#f1){ref-type="fig"}, inset). In addition, we tested rHcp for any residual LPS and found less than 1 endotoxin unit in 10 μg of the recombinant protein, which has no influence on macrophage activation.

Hcp decreases the survival rate of mice infected with the Δ*act/*Δ*vasH* mutant of *A. hydrophila* SSU
------------------------------------------------------------------------------------------------------

Since the secreted form of Hcp decreased bacterial phagocytosis, and we showed earlier that mice infected via the i.p. route with the Δ*vasH* mutant had a better survival rate compared with mice infected with the WT strain ([@r49]), we hypothesized that bacteria producing Hcp would have a better chance of evading the innate immunity and causing systemic effects. Hence, we challenged mice with a sublethal dose of the Δ*act/*Δ*vasH* mutant together with rHcp at different concentrations and monitored deaths for 16 days. We found that the addition of rHcp decreased the survival rates of mice after infection with the Δ*act/*Δ*vasH* mutant, with 100 % of the mice dying with 5 and 10 μg of rHcp (Fig. [2](#f2){ref-type="fig"}). These data indicated complementation of the above mutant with exogenous rHcp in terms of bacterial virulence.

Hcp enhances the spread of the Δ*act/*Δ*vasH* mutant of *A. hydrophila* SSU in a mouse model
--------------------------------------------------------------------------------------------

Since our data showed that the presence of rHcp increased the death rate of mice infected with sublethal doses of the Δ*act/*Δ*vasH* mutant, we evaluated the bacterial load in mouse organs after 48 h of infection in the presence of rHcp. Our results indicated that rHcp allowed the mutant bacteria to spread more efficiently to different organs (lungs, livers and spleens) possibly resulting in the animals\' death due to a systemic effect (Fig. [3](#f3){ref-type="fig"}). These bacterial numbers in different organs of mice infected with the Δ*act*/Δ*vasH* mutant in the presence of rHcp were very similar to their numbers reported recently from mouse organs after infection with the Δ*act* parental strain of *A. hydrophila* ([@r46]). Our results supported the prediction that Hcp played a role in innate immunity by avoiding bacterial clearance in the peritoneal cavity by phagocytosis, thus allowing organisms to multiply and spread to various organs.

Hcp binds to intraperitoneal immune cells of mice
-------------------------------------------------

Our earlier study showed that Hcp present in the conditioned medium of the WT strain of *A. hydrophila* SSU was able to bind RAW 264.7 macrophages ([@r49]). To confirm that Hcp also binds to primary macrophages, we collected whole cell populations from the peritoneal cavity of naïve mice and, after incubating them with rHcp *ex vivo*, we performed a multicoloured flow cytometry analysis by using antibodies against Hcp, F4/80 and Gr-1. Fig. [4(a)](#f4){ref-type="fig"} shows the forward scatter versus the side scatter plot from the whole cell population isolated after the lavage. For analysis, we evaluated rHcp binding to cells gated on F4/80 (macrophages) (Fig. [4b](#f4){ref-type="fig"}) and on Gr-1 (granulocytes) (Fig. [4c](#f4){ref-type="fig"}). As can be seen, rHcp was able to bind macrophages (Fig. [4d](#f4){ref-type="fig"}) and granulocytes (Fig. [4e](#f4){ref-type="fig"}), although the differential shift of the curve for granulocytes indicated that rHcp binding to this particular cell type was much less compared with its isotype control and that for the macrophages.

Hcp modulates the expression of activation markers on intraperitoneal immune cells
----------------------------------------------------------------------------------

Since our data indicated that rHcp binds to cells involved in the innate immune response, we analysed, by flow cytometry, the status of these cells after 4 h of infection with the Δ*act/*Δ*vasH* mutant of *A. hydrophila* given along with two different doses of rHcp. Specifically, we analysed changes in the percentage of macrophages (F4/80), granulocytes (Gr-1) and DCs (CD11c). In addition, we examined the expression of CD69 (an early activation marker) and the major histocompatibility complex (MHC) class II. As controls, we used lavages from uninfected (given only PBS) mice, infected with the Δ*act/*Δ*vasH* mutant of *A. hydrophila* alone along with PBS, and injected via the i.p. route with rHcp alone.

We noted a significant increase in the percentage of Gr-1-positive cells in the peritoneal cavity of animals infected with the Δ*act/*Δ*vasH* mutant when compared with the uninfected mice (Fig. [5a](#f5){ref-type="fig"}). However, this difference was independent of the presence of rHcp. Additionally, our results showed no significant changes in the percentage of macrophages and DCs in the peritoneal cavity after 4 h of infection, although we noted marginal increases in CD11c-positive cells (not statistically significant) related to the increasing concentrations of rHcp (Fig. [5a](#f5){ref-type="fig"}).

We then analysed the expression of CD69 and MHC class II in the total cell population as well as in cells gated for F4/80, Gr-1 and CD11c after cells were infected with the Δ*act/*Δ*vasH* mutant and given rHcp. As shown in Fig. [5(b)](#f5){ref-type="fig"}, the percentage of CD69 in F4/80- and Gr-1-positive cells decreased, and these decreases were dependent on the dose of rHcp used. Likewise, the percentage of MHC class II-positive cells in F4/80 cells decreased after mice were infected with the Δ*act/*Δ*vasH* mutant and given the higher dose of rHcp. However, the expression of MHC-class II showed an increase in CD11c cells (with 10 μg rHcp), although the data were not statistically significant (Fig. [5c](#f5){ref-type="fig"}). Likewise, injection of rHcp alone did not significantly change the percentage of CD69 and MHC class II in any of the cell types analysed compared with the uninfected group of mice.

Hcp modifies cytokine/chemokine production profiles induced by the *A. hydrophila* SSU Δ*act/*Δ*vasH* mutant
------------------------------------------------------------------------------------------------------------

Since rHcp modulates the expression of activation markers on macrophages, granulocytes and DCs, we analysed cytokine/chemokine patterns induced by the Δ*act/*Δ*vasH* mutant in the peritoneal cavity after 4 h of infection (Table [1](#t1){ref-type="table"} and Fig. [6](#f6){ref-type="fig"}). We found that infection of mice with the mutant induced the production of a wide range of pro- and anti-inflammatory cytokines/chemokines and growth factors. However, the addition of rHcp, along with the Δ*act/*Δ*vasH* mutant, during infection significantly modified the levels of some of these cytokines/chemokines. Thus, the concentrations of IL-2, IL-10, IL-15, IL-12p70, macrophage inflammatory protein (MIP)-1*β*, MIP-2, granulocyte colony-stimulating factor (G-CSF), IL-6, and keratinocyte-derived chemokine (KC) were increased by adding rHcp; however, the production of gamma interferon (IFN-*γ*), IL-1*α* and macrophage colony-stimulating factor (M-CSF) was inhibited (Table [1](#t1){ref-type="table"} and Fig. [6](#f6){ref-type="fig"}). On the other hand, intraperitoneal lavages from mice injected with rHcp alone showed low or non-detectable levels of cytokines/chemokines (Table [1](#t1){ref-type="table"}).

Hcp induces an alternative pathway of macrophage activation
-----------------------------------------------------------

Activation of macrophages is an important mechanism in innate immunity against foreign invading organisms. There are two types of macrophage activation. M1 or classical activation is mainly a pro-inflammatory or T helper (Th)1-like response focused on removal and clearing of the infection or debris produced by an injury, and M2 or alternative activation is focused more on tissue remodelling and wound healing. The latter is characterized by a low infiltration of cellular components and a Th2-like cytokine phenotype. Our data indicated that the presence of rHcp during infection with the Δ*act/*Δ*vasH* mutant could modulate an alternative pathway of macrophage activation, which is supported by decreases in some pro-inflammatory cytokine levels, such as IFN-*γ* and IL-1*α*, and increases in anti-inflammatory cytokines, such as TGF-*β*, IL-6, IL-9 and IL-10 (Table [1](#t1){ref-type="table"} and Fig. [6](#f6){ref-type="fig"}). These results were also supported by the low levels of M-CSF and tumour necrosis factor (TNF)-*α* induced by infection with the Δ*act/*Δ*vasH* mutant in mice, which remained unaltered in the presence of rHcp (Table [1](#t1){ref-type="table"} and Fig. [6](#f6){ref-type="fig"}). Taken together, these results correlated with the minimal macrophage recruitment in the peritoneal cavity of mice after infection with the Δ*act/*Δ*vasH* mutant of *A. hydrophila* SSU (Fig. [5a](#f5){ref-type="fig"}, F4/80 panel).

DISCUSSION
==========

In this report, we described the role of the secreted form of Hcp in modulating the innate host immune response, specifically by inhibiting phagocytosis by macrophages. It has been reported that some bacterial proteins are able to interfere with phagocytosis by inducing host cell apoptosis, especially via caspase-1 activation ([@r1]; [@r12]). We also showed that episomal expression of the *hcp* gene in epithelial cells induced apoptosis ([@r49]); however, there are no available data to show whether extracellular Hcp has any effect on the viability of eukaryotic cells. Based on 7-AAD and MTT assays, we did not detect any significant toxicity in macrophages which could be associated with rHcp until up to 24 h of incubation, except for a small increase in mitochondrial activity (measured by MTT) detected after 2 h of incubation. We believe this initial increase was due to the activation of macrophages by rHcp. Also, we found an increase in the percentage of 7-AAD-positive cells (∼6 % of the total population) as well as a decrease in the mitochondrial activity at 24 h that could be related to cell death after stimulation with rHcp. Since our experiments did not require incubation times longer than 4 h, we consider that the inhibition of phagocytosis *in vitro* due to Hcp present in the medium was independent of any toxic effects of Hcp on macrophages. Additionally, growth curves of the *A. hydrophila* Δ*act* and Δ*act/*Δ*vasH* mutant strains were similar, indicating that differences in phagocytosis of the *A. hydrophila* Δ*act/*Δ*vasH* mutant compared with that of its parental strain were not related to any differences in growth rates caused by the deletion of the *vasH* gene.

There are several examples of bacterial proteins that target phagocytosis at different levels in order to establish an infection. Our results showed that the secretion of Hcp into the extracellular medium played an important role in inhibiting innate immunity mediated by macrophages *in vitro*. Similarly, the presence of rHcp during infection increased bacterial virulence and allowed bacterial spread to different mouse organs after infection with the *A. hydrophila* Δ*act/*Δ*vasH* mutant. These data indicated that the increased virulence of this mutant in the presence of Hcp was associated with the inhibition of phagocytosis.

Macrophages, immature DCs and granulocytes are the main components of innate immunity and the first line of defence against invading organisms. Previously, we reported that the secreted form of Hcp binds RAW 264.7 macrophages ([@r49]). In this report, we extended this observation and tested the binding of rHcp to primary intraperitoneal cells. We found that rHcp bound mainly to macrophages, although some binding to granulocytes was also detected. We speculate that differences in Hcp binding between macrophages and granulocytes could be related to differences in the Hcp-binding receptor(s) on these two cell types. Additionally, we tested binding of rHcp to human epithelial cell lines, such as HT-29 and HeLa. We found that rHcp bound to HeLa and HT-29 cells at levels that were five and nine times lower, respectively, compared with RAW cells (data not shown). Together, these data suggest that macrophages are the major cell target for Hcp.

Analysis of cytokine/chemokine levels in peritoneal lavages showed increases, dependent on the dose of rHcp used, in those involved in granulocyte/neutrophil recruitment and maturation, such as G-CSF, KC and MIP-2. These data may suggest that Hcp does not affect the recruitment of granulocytes in the peritoneal cavity of mice after infection with the Δ*act/*Δ*vasH* mutant; however, reduction in CD69 levels on the surface of granulocytes in an rHcp dose-dependent manner indicates that this T6SS effector could have an effect on granulocyte activation.

The percentage of DCs (CD11c) was somewhat increased in mice infected with the Δ*act/*Δ*vasH* mutant in the presence of rHcp. Importantly, these cells also showed increases (although not reaching statistical significance) in the percentage of the MHC class II molecules in the presence of rHcp. These results led us to suggest that Hcp might be inducing the maturation of DCs (CD11c^+^/ MHC class II^+^); nonetheless, low levels of IL-12p70 and IFN-*γ*, and induction of IL-10 by rHcp in mice infected with the Δ*act/*Δ*vasH* mutant would hamper their normal activation and induction of regulatory phenotypes.

Macrophage activation is an important step in the modulation of immune responses, and a subdivision of alternative activation (M2) called 'deactivation' is mediated by the production of immunosuppressive cytokines IL-10 and TGF-*β*, downregulation of MHC class II molecules and pro-inflammatory cytokines/chemokines, low levels of IL-4 and IL-13 production, and finally low levels of production of reactive oxygen and nitrogen intermediates ([@r18]; [@r22]; [@r34]). This kind of activation could predispose the host to infection by the induction of regulatory cells which are inhibitors of inflammation, even in the presence of inflammatory cytokines/chemokines ([@r19]; [@r31]; [@r35]; [@r36]). In accordance, we found that the pattern of cytokines/chemokines in the peritoneal cavity after 4 h of infection with the *A. hydrophila* Δ*act/*Δ*vasH* mutant in the presence of rHcp, was indicative of an alternative pathway of activation or 'deactivation' of macrophages led by the production of IL-10 and TGF-*β*, decreases in IFN-*γ*, low levels of TNF-*α*, and no detection of IL-4 and IL-13.

IL-6 is an important modulator of the immune response due to its dual role as a Th1 cytokine, inducing the recruitment of cellular components, or as a Th2 cytokine, inhibiting the production of IFN-*γ* and enhancing the production of IL-10 by induction of suppressor of cytokine signalling (SOCS) proteins ([@r13]; [@r14]). In our study, we found that the Δ*act/*Δ*vasH* mutant induced the secretion of high levels of IL-6 in the intraperitoneal cavity, which was even higher when rHcp was present. We believe that IL-6 together with IL-10 and TGF-*β*, and low levels of IFN-*γ* and TNF-*α*, has a role in the differentiation of immune cells present in the peritoneal cavity by induction of SOCS-1 and -3. The SOCS family of regulators are involved in the suppression of nuclear factor-*κ*B signalling pathways, as well as in promoting IL-10 production ([@r14]). On the other hand, TGF-*β*, IL-9 and IL-10 also promote the production of SOCS proteins, which have been associated with impaired production of TNF-*α*, downregulation of nitric oxide synthase, and the expression of the IL-1ra antagonist gene ([@r4]; [@r28]).

We previously reported that immunization of mice with rHcp conferred protection against future infections with lethal doses of WT *A. hydrophila* SSU ([@r49]). Overall, the results reported in this study highlighted the importance of Hcp in early stages of *A. hydrophila* infection. Therefore, adaptive immunity mediated by antibodies could neutralize the effect that Hcp has on inhibition of phagocytosis and, thus, enhance bacterial clearing by opsonization-mediated phagocytosis.

We also have characterized other *A. hydrophila* SSU toxins with enzymic activities that could impair phagocytosis. For example, VgrG1, a T6SS effector protein, has actin-ADP-ribosylation activity ([@r50]), and the type 3 secretion system effector protein AexU, has ADP-ribosyltransferase and Rho--GAP activities ([@r44]; [@r45], [@r46]). Overall, *A. hydrophila* SSU has developed multiple mechanisms to circumvent innate immunity in order to establish an infection, and the role for each of these mechanisms in the disease process may depend on the host environment as well as the stage of infection.

In summary, Hcp binds to macrophages and induces the production of immunosuppressive cytokines IL-10 and TGF-*β* which results in impaired recruitment and inhibition of phagocytosis. This is the first report, to our knowledge, that highlights how T6SS effector Hcp modulates the activation of macrophages to cause systemic infection in a mouse model. We focused our study on only one isolate of *A. hydrophila*. Whether other species of *Aeromonas* harbouring the T6SS behave similarly needs to be further elucidated.
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A supplementary figure, showing the effect of Hcp and rHcp on bacterial growth and murine macrophages, is available with the online version of this paper.

![Hcp inhibits phagocytosis of the Δ*act/*Δ*vasH* mutant of *A. hydrophila* SSU by RAW 264.7 murine macrophages. (a) Western blot analysis of the conditioned medium from the parental Δ*act* strain of *A. hydrophila* by using antibodies to Hcp. The presence of a doublet on the Western blot may represent the degradation product of Hcp. (b) Conditioned medium containing Hcp inhibits phagocytosis of the Δ*act/*Δ*vasH* mutant. Phagocytosis assay using the *A. hydrophila* Δ*act/*Δ*vasH* mutant and RAW 264.7 cells was performed in conditioned medium from *A. hydrophila* SSU Δ*act* parental strain as the exogenous source of Hcp (mid-grey). We also used conditioned medium from *A. hydrophila* Δ*act/*Δ*vasH* mutant as a control for any other secreted proteins/factors independent of the T6SS that could affect phagocytosis (dark grey). Another control included fresh DMEM supplemented with 0.5 % FBS (light grey). Data shown are the mean±[sd]{.smallcaps} of three independent experiments. (c) rHcp inhibits phagocytosis of the *A. hydrophila* Δ*act/*Δ*vasH* mutant. As a control, we included *A. hydrophila* Δ*act/*Δ*vasH* mutant without rHcp, as well as the *A. hydrophila* Δ*act* parental strain. Data shown are the mean±[sd]{.smallcaps} of three independent experiments. The statistical difference was calculated by a one-way ANOVA test. \**P*\<0.05; \*\**P*\<0.01. The Coomassie Blue stained gel (inset) shows the purity of rHcp obtained after purification and removal of LPS. The lanes were loaded with 5 μg (lane 1) and  10 μg (lane 2) of rHcp. The physiological amount of Hcp produced by the parental strain of *A. hydrophila* was up to 8--10 μg in the peritoneum after infection.](3678fig1){#f1}

![rHcp increases the virulence of the *A. hydrophila* SSU Δ*act/*Δ*vasH* mutant. Survival curves of mice (*n*=10) infected via the i.p. route with 8×10^6^ c.f.u. of *A. hydrophila* Δ*act/*Δ*vasH* mutant in the presence of different concentrations of rHcp. As a control, groups of mice (*n*=10) were infected with the same doses of the mutant bacteria without rHcp or the Δ*act* parental strain. As another control for rHcp toxicity, mice were inoculated with the highest concentration of rHcp without the bacteria. The deaths were recorded for 16 days after infection. Asterisks represent groups of mice with statistically significant differences in mortality against the same doses of bacteria without the rHcp, *P*\<0.05. Each animal experiment was performed in duplicate and a representative experiment is shown.](3678fig2){#f2}

![rHcp plays a role in the spread of *A. hydrophila* SSU Δ*act/*Δ*vasH* mutant to different mouse organs. Bacterial burden was measured in the lungs, livers and spleens 48 h after i.p. infection with 3×10^7^ c.f.u. *A. hydrophila* Δ*act/*Δ*vasH* mutant in the presence of rHcp (10 μg) (mid-grey). Mice infected with the same dose of bacteria without rHcp were used as a control (light grey). The data were normalized with the organ weights. The graph represents data from 10 mice per group. Error bars show [sd]{.smallcaps}.](3678fig3){#f3}

![rHcp binds to intraperitoneal immune cells. Total intraperitoneal cells were recovered after peritoneal lavages and incubated with rHcp (10 μg) *ex vivo*. Subsequently, the cells were stained by using antibodies against Hcp (FITC), Gr-1 (PE) and F4/80 (PE-Cy5). (a) Side scatter versus forward scatter plot for the total intraperitoneal cells. (b) Side scatter versus F4/80 PE-Cy5 plot from the total cell population gated for the F4/80 positive cells (red). (c) Side scatter versus Gr-1 PE plot from the total cell population gated for the Gr-1-positive cells (blue). (d) A histogram plot showing staining for Hcp (Alexa Fluor 488) in cells which were F4/80 positive. The empty curve represents the isotype control, while the filled curve (red) represents cells incubated with anti-Hcp antibodies. (e) A histogram plot showing staining for Hcp (Alexa Fluor 488) in cells that were Gr-1 positive. The empty curve represents the isotype control and the filled curve (blue) represents cells incubated with anti-Hcp antibodies.](3678fig4){#f4}

![rHcp modulates the levels of activation markers on intraperitoneal innate immune cells of mice. Flow cytometric analysis of intraperitoneal cells recovered from lavages 4 h after infection with 3×10^7^ c.f.u. *A. hydrophila* SSU Δ*act/*Δ*vasH* mutant in the presence of different doses of rHcp (1 and 10 μg). The PBS group represents animals challenged with only bacteria and PBS in place of rHcp. (a) Percentage of positive cells for F4/80 (macrophages), Gr-1 (granulocytes) and CD11c (DCs). (b) and (c) Percentage of positive cells expressing CD69 (b) and MHC class II (c) for the total population or for cells gated for F4/80, Gr-1 or CD11c. Statistically significant differences were measured by the one-way ANOVA test followed by Tukey\'s test. \**P*\<0.05; \*\**P*\<0.01. Error bars indicate [sd]{.smallcaps}.](3678fig5){#f5}

![rHcp induces an alternative pathway of macrophage activation in the peritoneal lavages of mice infected with 3×10^7^ c.f.u. *A. hydrophila* SSU Δ*act/*Δ*vasH* mutant in the presence of different doses of rHcp (1 and 10 μg), as determined by cytokine/chemokine profiling. Cytokines were measured by multiplex bead array on samples of intraperitoneal cavity lavages 4 h after infection. Statistically significant differences were measured by the one-way ANOVA test, followed by Tukey\'s test. \**P*\<0.05; \*\**P*\<0.01; \*\*\**P*\<0.001. Error bars indicate [sd]{.smallcaps}.](3678fig6){#f6}

###### 

Cytokine/chemokine levels in the peritoneal lavages of mice

Concentrations are in pg ml^−1^; mean±[sd]{.smallcaps}. [nd]{.smallcaps}, Not detected.

  **Cytokine/chemokine\***   ***A. hydrophila* SSU Δ*act/*Δ*vasH* mutant**   **rHcp (10 μg)**   
  -------------------------- ----------------------------------------------- ------------------ ------------------
  Eotaxin                    1018±58                                         1088±35            120±38
  G-CSF                      126849±18670                                    184895±11335†      434±108
  GM-CSF                     128±12                                          142±24             13±2
  IFN-*γ*                    414±70                                          183±39§            [nd]{.smallcaps}
  IL-1*α*                    276±11                                          240±14†            18±5
  IL-1*β*                    811±68                                          872±90             [nd]{.smallcaps}
  IL-2                       12±3                                            27±12‡             [nd]{.smallcaps}
  IL-3                       [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}
  IL-4                       [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}
  IL-5                       129±22                                          100±18             [nd]{.smallcaps}
  IL-6                       62608±11044                                     118731±22410†      398±105
  IL-7                       [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}
  IL-9                       141±11                                          209±6‡             49±5
  IL-10                      109±32                                          192±32†            [nd]{.smallcaps}
  IL-12p40                   [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}
  IL-12p70                   123±3                                           133±3†             8±2
  IL-13                      [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}
  IL-15                      14±1                                            20±0.5§            [nd]{.smallcaps}
  IL-17                      1332±112                                        1774±259           [nd]{.smallcaps}
  IP-10                      413±33                                          395±19             198±73
  KC                         19104±4320                                      36500±6353†        47±27
  LIF                        [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}
  LIX                        560±55                                          568±11             38±10
  MCP-1                      16108±1562                                      17860±711          200±73
  M-CSF                      12±2                                            7±2‡               [nd]{.smallcaps}
  MIG                        2180±173                                        1919±96            55±23
  MIP-1*α*                   401±29                                          481±18             86±7
  MIP-1*β*                   526±76                                          734±61†            60±17
  MIP-2                      6288±935                                        10754±633†         20±5
  RANTES                     207±15                                          238±17             14±3
  TNF-*α*                    16±2                                            22±3               [nd]{.smallcaps}
  VEGF                       [nd]{.smallcaps}                                [nd]{.smallcaps}   [nd]{.smallcaps}

\*GM-CSF, granulocyte-macrophage colony-stimulating factor; LIF, leukaemia inhibitory factor; LIX, LPX-inducible CXC chemokine; MCP, monocyte-chemoattractant protein; MIG, monocyte induced by IFN-*γ*; VEGF, vascular endothelial growth factor.

†*P*\<0.05 compared with + PBS.

‡*P*\<0.01 compared with + PBS.

§*P*\<0.001 compared with + PBS.
